A European project will test the results of a research on myotonic dystrophy type 1 in which the University of Valencia has participated
- Scientific Culture and Innovation Unit
- September 26th, 2019
A research project of the Marató-TV3 to develop new treatments for type 1 myotonic dystrophy (DM1), led by the Translational Genomic Research Group of the University of Valencia (UV), identified one of its components, which was patented by UV and others, and licensed to Myogem Health Company. The company has developed an improved formulation that is marketed as a food supplement. The European project granted to Myogem will allow the product to undergo the pilot clinical trial in 15 DM1 patients.
Myotonic dystrophy is an incurable rare neuromuscular disease without specific treatment that affects almost one million people in the world. It causes chronic weakness and shortens the life expectancy. Among genetic diseases, its therapeutic treatment is relatively favourable, given that it originates due to the lack of activity of MBNL proteins, highlights Rubén Artero, professor of Genetics at the University of Valencia, coordinator of the Translational Genomics Research Group and investigator of INCLIVA.
Myogem Health Company S.L. and its project “New food for special medical uses for the nutritional management of Type 1 Miotonic Dystrophy” have been awarded by the European Commission in the Horizon 2020 SME Instrument Phase 1 research program with two stamps of excellence and financing to carry out the clinical study of the MYODM food supplement. The study will be carried out at the Donostia University Hospital, Biodonostia Institute since October.
Based on the results of the clinical study, Myogem aims to transform the current nutritional supplement into foods for special medical uses, specially prepared or formulated foods intended for the patient’s dietary management, under medical supervision.
The pilot clinical study will be carried out under the direction of Roberto Fernández Torrón, neurologist with extensive experience in DM1. The study is expected to start in October 2019, and results and conclusions in July 2020, highlighted in a statement Myogem Health Company, a company dedicated to the research, development and marketing of food supplements and food for special medical uses aimed at improving the quality of life of people affected by minority illnesses.
File in: Recerca, innovació i transferència , Facultat de Ciències Biològiques , Genètica , Investigació a la UV , Internacionalització recerca , Col·laboració amb empresa , Grups de recerca , Difusió i comunicació científica